Myriad Genetics (MYGN - Get Report) is a molecular diagnostic company. Myriad Genetics is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of the molecular diagnostic testing and analysis for its tests in its own reference laboratory. This stock is trading up 5% at $23.94 in recent trading.
Today's Volume: 1.3 millionAverage Volume: 664,112 Volume % Change: 284% Shares of MYGN are ripping higher today after the Supreme Court made a decision to remand back to the Court of Appeals Federal Circuit a patent case between ACLU and Myriad Genetics. From a technical perspective, MYGN are rising sharply today back above its 50-day moving average of $23.59 on heavy volume. Traders should now look for more upside and long biased trades if MYGN can take out some near-term overhead resistance around $24.50 with high-volume. Look for volume on that move that's near or well above 664,112 shares. If we get that action today or soon, then look for MYGN to re-test its recent high of $25.75. Myriad shows up on a list of 4 Upgraded, Undervalued Stocks.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts